Insomnia - Pipeline Review, H2 2015 Is Released Insomnia - Pipeline Review, H2 2015 Summary Global Markets Direct s, Insomnia - Pipeline Review, H2 2015, provides an overview of the Insomnias therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Insomnia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Insomnia and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Insomnia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Insomnia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Insomnia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Insomnia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Insomnia Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Insomnia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
1
with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173373/insomniapipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173373/insomnia-pipeline-review-h2-2015 Table of Contents
Introduction 8 Global Markets Direct Report Coverage 8 Insomnia Overview 9 Therapeutics Development 10 Pipeline Products for Insomnia - Overview 10 Pipeline Products for Insomnia - Comparative Analysis 11 Insomnia - Therapeutics under Development by Companies 12 Insomnia - Therapeutics under Investigation by Universities/Institutes 14 Insomnia - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Insomnia - Products under Development by Companies 18 Insomnia - Products under Investigation by Universities/Institutes 19 Insomnia - Companies Involved in Therapeutics Development 20 Alexza Pharmaceuticals, Inc. 20 Eisai Co., Ltd. 21 Evotec AG 22 Grupo Ferrer Internacional, S.A. 23 Heptares Therapeutics Limited 24 Intec Pharma ltd. 25 Intra-Cellular Therapies, Inc. 26 2
Johnson & Johnson 27 Merck & Co., Inc. 28 Neurim Pharmaceuticals Ltd 29 Novartis AG 30 Reviva Pharmaceuticals Inc. 31 Rottapharm SpA 32 Shionogi & Co., Ltd. 33 Somnus Therapeutics, Inc. 34 Takeda Pharmaceutical Company Limited 35 Insomnia - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 44 CB-2810 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 CR-5542 Series - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Drugs to Inhibit Angiotensin II Receptor Type 1 for Insomnia - Drug Profile 46 Product Description 46
3
Mechanism of Action 46 R&D Progress 46 EVT-201 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 HTL-6641 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 ITI-007 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 JNJ-42847922 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 LASSBio-785 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 LASSBio-786 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 lemborexant - Drug Profile 55 4
Product Description 55 Mechanism of Action 55 R&D Progress 55 lorediplon - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 MK-1064 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 MK-8133 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 NEO-1940 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 piromelatine - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 ramelteon - Drug Profile 62 Product Description 62 Mechanism of Action 62
5
R&D Progress 62 S-117957 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Small Molecule for Obesity and Insomnia - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Small Molecule to Inhibit OX2R for Insomnia - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 UCM-765 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 zaleplon - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 zaleplon - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 zaleplon DR - Drug Profile 70 Product Description 70 6
Mechanism of Action 70 R&D Progress 70 zolpidem tartrate - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Insomnia - Recent Pipeline Updates 73 Insomnia - Dormant Projects 82 Insomnia - Discontinued Products 84 Insomnia - Product Development Milestones 85 Featured News & Press Releases 85 Sep 24, 2015: Minerva Neurosciences Provides Update on Clinical Development Program With MIN-202, Selective Orexin-2 Receptor Antagonist 85 Jul 14, 2015: Ferrer initiates phase IIa clinical study of Lorediplon in patients with insomnia 85 Jun 16, 2015: Minerva Neurosciences Provides Update on MIN-202, Selective Orexin-2 Receptor Antagonist 86 Jan 21, 2015: Minerva Neurosciences Reports Positive Phase 1 Data with MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia 87 Dec 10, 2014: Eisai Demonstrates Efficacy of Investigational Dual Orexin Receptor Antagonist E2006 in Sleep Initiation and Maintenance 88 Sep 22, 2014: Minerva Neurosciences Announces Completion of FDA Review of Investigational New Drug Application for MIN-202 and Plans for First U.S.-Based Clinical Trial 89 Jul 26, 2013: Takeda Pharma Receives FDA Approval for Rozerem 89 Feb 18, 2013: Neurim Pharma Announces Positive Phase II Clinical Trial Results Of Piromelatine For Treatment Of Insomnia 90 Feb 09, 2012: Ferrer Announces Positive Results From Phase I Clinical Trials of Lorediplon In Insomnia 90 Dec 14, 2011: McGill University Health Centre Researchers Discover Potential Insomnia Drug 91 Appendix 93 Methodology 93
7
Coverage 93 Secondary Research 93 Primary Research 93 Expert Panel Validation 93 Contact Us 93 Disclaimer 94
Read More http://www.idatainsights.com/reports-landing-page.php?id=173373/insomnia-pipelinereview-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
8
9